Please login to the form below

Not currently logged in
Email:
Password:

orlaratumab

This page shows the latest orlaratumab news and features for those working in and with pharma, biotech and healthcare.

Lilly bags EU approval for cancer treatment Lartruvo

Lilly bags EU approval for cancer treatment Lartruvo

Licensed for use with doxorubicin for soft tissue sarcoma patients. The European Commission has granted Lilly's Lartruvo (orlaratumab) marketing authorisation for the first-line treatment of patients with advanced soft

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics